PapersPMID:36904283
Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Likewise, we did not detect any lactoferrin effects on the need for oxygen supplementation and its duration, non-invasive or mechanically assisted ventilation, or in-hospital mortality at 14 and 28 days from admission (Table 4).”
- Study
- RCT
- Duration
- 4 weeks
- Dose studied
- 800 mg/day bovine lactoferrin, 2 capsules of 200 mg every 12 h before meals, for 30 days
- Population
- Adults hospitalised in non-ICU wards with moderate-to-severe COVID-19 at two Italian hospitals, standard COVID-19 therapy in both arms; in-hospital mortality at 14 and 28 days
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Hospitalized adult patients with moderate-to-severe COVID-19 in non-ICU COVID-19 wards at two Italian hospitals (LAC trial); oral bovine lactoferrin (Mosiac) added to standard COVID-19 therapy
- Participants
- 218
- Comparator
- placebo
- Duration
- 30 days
- Endpoints measured
- 22